We conducted the Next Generation Trial, which was a validating paired-cohort trial comparing fluorine-18 prostate-specific membrane antigen-1007 PET/computed tomography (18F-PSMA-1007 PET/CT) to MRI for the primary locoregional staging of intermediate and high-risk prostate cancers in men undergoing radical prostatectomy [3]. This evidence concerns the gene FOLH1 and prostate cancer.